R R

What Is Rinvoq?

Rinvoq is a prescription medication containing upadacitinib, a Janus kinase inhibitor used to treat selected inflammatory and immune-mediated diseases. It is approved for conditions affecting the joints, skin, digestive tract, and blood vessels, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, and giant cell arteritis. Rinvoq is available as extended-release oral tablets, while Rinvoq LQ is a separate oral solution for certain pediatric indications. The approved age groups and previous treatment requirements differ by condition. Rinvoq carries boxed warnings for serious infections, malignancies, major cardiovascular events, blood clots, and increased mortality.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rinvoq?

Rinvoq is a prescription medication containing upadacitinib, a Janus kinase inhibitor used to treat selected inflammatory and immune-mediated diseases. It is approved for conditions affecting the joints, skin, digestive tract, and blood vessels, including rheumatoid arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, and giant cell arteritis. Rinvoq is available as extended-release oral tablets, while Rinvoq LQ is a separate oral solution for certain pediatric indications. The approved age groups and previous treatment requirements differ by condition. Rinvoq carries boxed warnings for serious infections, malignancies, major cardiovascular events, blood clots, and increased mortality.

read more about rinvoq ...

Copy this HTML:

Copy HTML Copied!

How Does Rinvoq Work?

Rinvoq inhibits Janus kinase enzymes, particularly JAK1, which participate in signaling pathways used by inflammatory cytokines. These signaling proteins can stimulate immune cells and contribute to inflammation in the joints, skin, intestines, and other tissues. By interfering with JAK-mediated signaling, upadacitinib reduces the activity of selected inflammatory pathways. This can relieve symptoms and help control disease activity in eligible patients. Rinvoq does not permanently cure autoimmune or inflammatory conditions. Because JAK signaling also participates in normal immune responses and blood cell regulation, treatment can increase infection risk and produce laboratory abnormalities.

What Conditions Does Rinvoq Treat?

Rinvoq is approved for selected patients with rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, nonradiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. Many indications require an inadequate response or intolerance to previous treatments, including TNF blockers, while eligibility rules differ by condition. Certain pediatric indications begin at age two, with Rinvoq LQ available for specified children. Atopic dermatitis treatment is approved for patients aged 12 years and older who meet treatment criteria. A specialist evaluates disease severity, previous therapies, infection history, and cardiovascular or cancer risk before prescribing Rinvoq.

How Should Rinvoq Be Taken?

Rinvoq dosing depends on the condition, age, body weight, and formulation. Adults with rheumatoid arthritis commonly take 15 mg extended-release tablets once daily. Atopic dermatitis treatment may use 15 mg or 30 mg once daily in eligible patients. Ulcerative colitis and Crohn's disease use higher induction doses followed by lower maintenance doses. Giant cell arteritis generally uses 15 mg once daily with an appropriate corticosteroid taper. Extended-release tablets must be swallowed whole without crushing, splitting, or chewing. Rinvoq LQ has separate pediatric dosing and administration instructions. Patients require tuberculosis and hepatitis screening, blood tests, and vaccination review before treatment.

What Are the Side Effects and Warnings of Rinvoq?

Common adverse effects can include upper respiratory infections, nausea, acne, headache, and elevated cholesterol levels, with frequencies varying by indication. Rinvoq carries boxed warnings for serious infections, including tuberculosis and opportunistic infections, lymphoma and other malignancies, major adverse cardiovascular events, thrombosis, and mortality. Other serious risks include gastrointestinal perforation, liver enzyme abnormalities, reduced blood cell counts, and serious allergic reactions. Rinvoq should generally not be combined with other JAK inhibitors or potent immunosuppressants. Clinicians monitor blood counts, liver tests, lipids, and infection symptoms. Persistent fever, chest pain, sudden weakness, severe abdominal pain, or leg swelling requires urgent medical attention.

Common Questions About Rinvoq

Is Rinvoq the same as upadacitinib?

Yes. Rinvoq contains upadacitinib, a Janus kinase inhibitor prescribed for selected inflammatory and autoimmune conditions.

Can Rinvoq treat eczema?

Yes. Rinvoq is approved for refractory moderate to severe atopic dermatitis in eligible adults and adolescents aged 12 years and older.

Can children take Rinvoq?

Yes. Certain Rinvoq indications include pediatric patients, with minimum ages and formulation requirements depending on the condition.

Is Rinvoq an immunosuppressant?

Rinvoq reduces selected immune signaling pathways and can increase susceptibility to serious infections. Patients require infection screening and monitoring.

References

DailyMed - RINVOQ (upadacitinib) extended-release tablets and RINVOQ LQ oral solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2966aec7-2ef0-923c-d8ff-fe1a957bf095. Date Accessed November 3, 2026.

Upadacitinib. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK574351/. Date Accessed November 3, 2026.

Upadacitinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a619051.html. Date Accessed November 3, 2026.

Upadacitinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/58557659. Date Accessed November 3, 2026.

Upadacitinib Drug Label Information. U.S. Food and Drug Administration. https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/380835. Date Accessed November 3, 2026.